Logo image of BCAT

BLACKROCK CAPITAL ALLOC TR (BCAT) Stock Price, Quote, News and Overview

NYSE:BCAT - New York Stock Exchange, Inc. - US09260U1097 - Currency: USD

15.36  -0.11 (-0.71%)

After market: 15.39 +0.03 (+0.2%)

Fundamental Rating

3

BCAT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. While BCAT seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, BCAT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BCAT was profitable.
BCAT had a positive operating cash flow in the past year.
BCAT Yearly Net Income VS EBIT VS OCF VS FCFBCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -1B -2B

1.2 Ratios

The last Return On Invested Capital (2.49%) for BCAT is above the 3 year average (2.16%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.1%
ROE 7.9%
ROIC 2.49%
ROA(3y)-0.14%
ROA(5y)N/A
ROE(3y)-0.49%
ROE(5y)N/A
ROIC(3y)2.16%
ROIC(5y)N/A
BCAT Yearly ROA, ROE, ROICBCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 5 -5 10 -10 -15

1.3 Margins

BCAT's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of BCAT has grown nicely.
BCAT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 70.06%
PM (TTM) 174.59%
GM 72.04%
OM growth 3Y22.71%
OM growth 5YN/A
PM growth 3Y-39.07%
PM growth 5YN/A
GM growth 3Y21.45%
GM growth 5YN/A
BCAT Yearly Profit, Operating, Gross MarginsBCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 500 1K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BCAT has been reduced compared to 1 year ago.
There is no outstanding debt for BCAT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAT Yearly Shares OutstandingBCAT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
BCAT Yearly Total Debt VS Total AssetsBCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

An Altman-Z score of 4.61 indicates that BCAT is not in any danger for bankruptcy at the moment.
There is no outstanding debt for BCAT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.61
ROIC/WACCN/A
WACCN/A
BCAT Yearly LT Debt VS Equity VS FCFBCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 1B -1B 2B -2B

2.3 Liquidity

A Current Ratio of 0.16 indicates that BCAT may have some problems paying its short term obligations.
A Quick Ratio of 0.16 indicates that BCAT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.16
BCAT Yearly Current Assets VS Current LiabilitesBCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 165.47% over the past year.
BCAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.32% yearly.
BCAT shows a decrease in Revenue. In the last year, the revenue decreased by -3.47%.
BCAT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 91.73% yearly.
EPS 1Y (TTM)165.47%
EPS 3Y18.32%
EPS 5YN/A
EPS Q2Q%350.1%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y91.73%
Revenue growth 5YN/A
Sales Q2Q%-1.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAT Yearly Revenue VS EstimatesBCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 20M 40M 60M 80M
BCAT Yearly EPS VS EstimatesBCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 8.04, which indicates a very decent valuation of BCAT.
When comparing the Price/Earnings ratio of BCAT to the average of the S&P500 Index (29.63), we can say BCAT is valued rather cheaply.
Industry RankSector Rank
PE 8.04
Fwd PE N/A
BCAT Price Earnings VS Forward Price EarningsBCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 5.68
EV/EBITDA N/A
BCAT Per share dataBCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

BCAT has a Yearly Dividend Yield of 18.51%, which is a nice return.
BCAT's Dividend Yield is rather good when compared to the S&P500 average which is at 2.27.
Industry RankSector Rank
Dividend Yield 18.51%

5.2 History

BCAT has been paying a dividend for over 5 years, so it has already some track record.
BCAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years4
BCAT Yearly Dividends per shareBCAT Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BCAT Yearly Income VS Free CF VS DividendBCAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 0 -1B -2B

More info and screens

BLACKROCK CAPITAL ALLOC TR

NYSE:BCAT (2/21/2025, 8:04:00 PM)

After market: 15.39 +0.03 (+0.2%)

15.36

-0.11 (-0.71%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners30.68%
Inst Owner Change-4.87%
Ins Owners0.3%
Ins Owner Change0.03%
Market Cap1.65B
Analysts0
Price TargetN/A
Short Float %0.08%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 18.51%
Yearly Dividend1.52
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years2
Div Non Decr Years4
Ex-Date02-14 2025-02-14 (0.28822)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 8.04
Fwd PE N/A
P/S 19.47
P/FCF 5.68
P/OCF 5.68
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)1.91
EY12.43%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)2.7
FCFY17.6%
OCF(TTM)2.7
OCFY17.6%
SpS0.79
BVpS17.44
TBVpS17.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.1%
ROE 7.9%
ROCE 3.15%
ROIC 2.49%
ROICexc 2.49%
ROICexgc 2.53%
OM 70.06%
PM (TTM) 174.59%
GM 72.04%
FCFM 342.69%
ROA(3y)-0.14%
ROA(5y)N/A
ROE(3y)-0.49%
ROE(5y)N/A
ROIC(3y)2.16%
ROIC(5y)N/A
ROICexc(3y)2.16%
ROICexc(5y)N/A
ROICexgc(3y)2.2%
ROICexgc(5y)N/A
ROCE(3y)2.79%
ROCE(5y)N/A
ROICexcg growth 3Y153.12%
ROICexcg growth 5YN/A
ROICexc growth 3Y154.33%
ROICexc growth 5YN/A
OM growth 3Y22.71%
OM growth 5YN/A
PM growth 3Y-39.07%
PM growth 5YN/A
GM growth 3Y21.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 196.28%
Current Ratio 0.16
Quick Ratio 0.16
Altman-Z 4.61
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)165.47%
EPS 3Y18.32%
EPS 5YN/A
EPS Q2Q%350.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y91.73%
Revenue growth 5YN/A
Sales Q2Q%-1.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.41%
EBIT growth 3Y135.28%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.79%
OCF growth 3YN/A
OCF growth 5YN/A